Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis

PURPOSE: Epidermal growth factor receptor (EGFR) T790M-negative/unknown advanced non-small cell lung cancer (NSCLC) patients lack subsequent approved targeted therapies. This meta-analysis aimed to assess the efficacy of osimertinib in advanced NSCLC patients with different T790M status after resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Xiao-Fang, Song, Jun, Gao, Ruo-Lin, Sun, Li, Wu, Zhi-Xuan, Zhang, Shu-Ling, Huang, Le-Tian, Ma, Jie-Tao, Han, Cheng-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242653/
https://www.ncbi.nlm.nih.gov/pubmed/35785185
http://dx.doi.org/10.3389/fonc.2022.863666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242653/
https://www.ncbi.nlm.nih.gov/pubmed/35785185
http://dx.doi.org/10.3389/fonc.2022.863666

Ejemplares similares